Autopsy report · NCT04068805

Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)

“The Sponsor chose to terminate this study for commercial reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 1 year 10 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Happify Inc.

Sponsor type

Industry

Conditions

Diabetes Mellitus, Type 2

Interventions

Happify

Participants

14

Sites

1

Countries

United States

Trials that died the same way

• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (92% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (91% match in meaning)
• Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
  “The Sponsor terminated the study.” (90% match in meaning)
• Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
  “Study terminated by sponsor for commercial reasons” (89% match in meaning)
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  “This study was terminated by the Sponsor.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.